Clinical trial
A Study of the Safety and Effectiveness of Galantamine in Patients With…
NCT00216502 · Janssen-Cilag S.p.A., Industry · Completed
Key facts
| NCT number | NCT00216502 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease |
| Official title | Long Term Treatment With Galantamine In Dementia |
| Lead sponsor | Janssen-Cilag S.p.A., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Dementia, Mental Disorders, Brain Diseases |
| Intervention type | Drug |
| Interventions | galantamine hydrobromide |
| Enrollment | 254 |
| Start date | Aug 1, 2001 |
| Completion | Nov 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: